Initialized

10x Science: The Founders Who Built the Field Are Now Building the Platform

10x Science is launching an AI‑driven platform that automates molecular characterization of biologic drugs, a step traditionally performed manually by PhD scientists using outdated software. The company’s founders—two Stanford‑trained researchers with Nobel‑linked publications and a veteran YC entrepreneur—bring deep scientific credibility and rapid execution. Pharma’s recent disappointment with AI‑focused discovery tools has shifted demand toward solutions that deliver immediate ROI, and 10x’s recurring‑revenue model fits that need. Early demos with major pharma firms have consistently progressed to contract negotiations, signaling strong product‑market fit.